| Literature DB >> 27471632 |
Benjamin Rengstl1, Frederike Schmid1, Christian Weiser1, Claudia Döring1, Tim Heinrich1, Kathrin Warner2, Petra S A Becker3, Robin Wistinghausen1, Sima Kameh-Var1, Eva Werling1, Arne Billmeier1, Christian Seidl3, Sylvia Hartmann1, Hinrich Abken4, Ralf Küppers5, Martin-Leo Hansmann1, Sebastian Newrzela1.
Abstract
Hodgkin lymphoma (HL) presents with a unique histologic pattern. Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually account for less than 1% of the tumor and are embedded in a reactive infiltrate mainly comprised of CD4(+) T cells. HRS cells induce an immunosuppressive microenvironment and thereby escape antitumor immunity. To investigate the impact of interactions between HRS cells and T cells, we performed long-term co-culture studies that were further translated into a xenograft model. Surprisingly, we revealed a strong antitumor potential of allogeneic CD4(+) T cells against HL cell lines. HRS and CD4(+) T cells interact by adhesion complexes similar to immunological synapses. Tumor-cell killing was likely based on the recognition of allogeneic major histocompatibility complex class II (MHC-II) receptor, while CD4(+) T cells from MHC-II compatible donors did not develop any antitumor potential in case of HL cell line L428. However, gene expression profiling (GEP) of co-cultured HRS cells as well as tumor infiltration of matched CD4(+) T cells indicated cellular interactions. Moreover, matched CD4(+) T cells could be activated to kill CD30(+) HRS cells when redirected with a CD30-specific chimeric antigen receptor. Our work gives novel insights into the crosstalk between HRS and CD4(+) T cells, suggesting the latter as potent effector cells in the adoptive cell therapy of HL.Entities:
Keywords: CD4+ T cells; Hodgkin and Reed-Sternberg (HRS) cells; Hodgkin lymphoma; MHC-II compatible donors; anti-tumor reaction; chimeric antigen receptor (CAR)
Year: 2016 PMID: 27471632 PMCID: PMC4938355 DOI: 10.1080/2162402X.2016.1160186
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110